Study on the Expression of ERCC1 and Prediction of Platinum-based Chemotherapy Sensitivity in Advanced Non-Small Cell Lung Cancer

Objective To determine the correlation of ERCC1 with advanced non-small cell lung cancer(NSCLC).Methods The expression of ERCC1 was examined by immuno-histochemical technique in 103 patients with advance non-small-cell lung cancer.The data of therapeutical effect were collected and analyzed,and the survival analysis was conducted.Results The expression of ERCC1 was 46.6% among 103 cases,and there was no correlation with patient age,clinical stage,pathology type and gender;The patients were divided into four groups.Patients in 1st group(n=24)had positive ERCC1 expression and received paclitaxel plus cisplatin chemotherapy(TP);Patients in 2nd group(n=24) had positive ERCC1 expression and received gemcitabine plus cisplatin chemotherapy(GP);Patients in 3rd(n=25)had negative ERCC1 expression and received paclitaxel plus cisplatin chemotherapy(TP);Patients in 4th group(n=30) had negative ERCC1 expression and received gemcitabine plus cisplatin chemotherapy(GP);The response rates of chemotherapy(CR+PR) in 4 groups were 16.7%,50.0%,52.0%,33.3%,respectively.There was significant difference in the response rate between group 1 and group 2(P0.05);The response rate in group 2 was similar with these of group 3 and group 4,there was no remarkable difference compared(P0.05).The survival analysis shows that four groups there were no statistical differences in the 4 groups(χ2=1.3589,P=0.7152).Conclusion The expression of ERCC1 was related to platinum-based chemotherapy sensitivity and could predict platinum-based chemotherapy sensitivity in advanced non-small-cell lung cancer.Genotypic make and adjust the competence of ERCC1 expression and improve the sensitivity of platinum-based chemotherapy.